Intas cuts Razumab supplies after adverse eye reactions

Razumab, a biosimilar of Genentech’s Lucentis, was launched in June at about 25 per cent cheaper than the innovator drug marketed by Novartis.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news